Business Overview: Neogen Corporation (Nasdaq: NEOG)

---

Executive Summary

Neogen Corporation is a Michigan-based life sciences company that develops, manufactures, and markets diagnostic and safety products for two closely related purposes: keeping the food supply safe and keeping animals healthy. Founded in 1981 and headquartered in Lansing, Michigan, Neogen's stated mission is "fueling a brighter future for global food security."

Neogen roughly doubled in scale on September 1, 2022, when it combined with 3M's Food Safety Division in a Reverse Morris Trust transaction — former 3M Food Safety shareholders ended up owning about 50.1% of the combined company. That deal made Neogen a clear global leader in food-safety diagnostics (test kits that detect pathogens, allergens, toxins, and contaminants) while retaining its long-standing Animal Safety business of veterinary pharmaceuticals, instruments, and genomics testing. In fiscal 2025 (ended May 31, 2025), the combined company generated $894.7 million in revenue.

---

1. Core Business Model & How They Work

Neogen sells consumable diagnostic test kits, reagents, and instruments to food producers, processors, and animal-health customers who need fast, reliable, repeatable safety testing — a razor/razorblade-style model built around regulatory necessity rather than discretionary purchasing.

[ R&D: Diagnostic Assay Development ] ➡️ [ Regulatory Validation / Certification ] ➡️ [ Instrument Placement at Customer Site ] ➡️ [ Recurring Consumable Test-Kit Sales ] ➡️ [ Customer Compliance / Recall Avoidance ]

Key Operational Drivers

1. Consumables-Driven Revenue: Once a food processor or lab validates a Neogen test method for a given pathogen or contaminant, it tends to keep re-ordering that specific kit rather than re-validating a competitor's — generating sticky, recurring revenue.
2. Regulatory Necessity, Not Discretion: Food safety testing is driven by government regulation and customer/retailer specifications (and the catastrophic cost of a recall), which makes demand far less cyclical than typical industrial or consumer products.
3. Post-Merger Integration: Since the 2022 3M Food Safety combination, Neogen has been integrating manufacturing, sales, and distribution networks; it also agreed in April 2025 to divest its global Cleaners and Disinfectants business, continuing to reshape the portfolio toward core diagnostics.
4. Global Reach: Sales outside the United States were 50.2% of fiscal 2025 revenue, with no single foreign country or customer representing 10% or more — a genuinely global, diversified customer base.

---

2. Business Segments

┌─────────────────────────────────────┐
│          Neogen Corporation          │
└──────────────────┬────────────────────┘
                    │
      ┌─────────────┴─────────────┐
      ▼                           ▼
┌───────────────────┐     ┌───────────────────┐
│   Food Safety      │     │  Animal Safety     │
│  (~71% of FY25 rev)│     │ (~29% of FY25 rev) │
└───────────────────┘     └───────────────────┘

Food Safety (~71.3% of FY2025 revenue, $638.1 million)

Diagnostic test kits and culture media detecting pathogens, spoilage organisms, natural toxins, and allergens across the food and feed supply chain — the segment inherited and scaled through the 3M Food Safety combination.

Animal Safety (~28.7% of FY2025 revenue, $256.5 million)

Veterinary instruments, pharmaceuticals, vaccines, parasiticides, rodent and insect control products, disinfectants, and genomics testing services for livestock and companion animals — Neogen's original, legacy business line.

---

3. Product Portfolio

---

4. Competitive Landscape

Neogen's 10-K explicitly states that no single competitor pursues its full strategy of a broad product line spanning both food and animal safety — its competitors are a patchwork of specialists and divisions of larger companies rather than one direct peer.

• Food Safety Diagnostics: Competes against divisions of large multinational life-science and instrument companies (e.g., Thermo Fisher Scientific, Bio-Rad, Hygiena, Romer Labs) and smaller specialized diagnostics firms, some with greater financial resources than Neogen.
• Animal Safety / Veterinary Products: Competes against companies such as Zoetis, Elanco, Boehringer Ingelheim Animal Health, and veterinary instrument/pharma suppliers, where Neogen is a smaller player relative to the segment's largest names.

Neogen's stated competitive approach is to win on ease of use, speed, and accuracy of testing, combined with product breadth across both food and animal safety, rather than competing purely on price.

---

5. Strategic Strengths & Risks

Strengths (The Moat)

• Validated, Regulatory-Embedded Test Methods: Once a customer's quality or compliance process is built around a specific Neogen assay, switching to a competitor requires costly re-validation — a real, if narrow, switching-cost moat.
• Scale from the 3M Combination: The 2022 merger gave Neogen a global manufacturing and distribution footprint in food safety that would be very expensive for a smaller competitor to replicate.
• Demand Driven by Regulation, Not Discretion: Food and feed safety testing is required by law and retailer specification in most major markets, insulating demand from ordinary consumer-spending cycles.

Risks

1. Margin Pressure from Integration: Gross margin fell to 47.1% in fiscal 2025 from 50.2% the prior year, and total revenue declined 3.2% to $894.7 million — showing the post-merger integration has not yet delivered the scale benefits the deal was premised on.
2. Portfolio Reshaping Risk: The April 2025 agreement to divest the Cleaners and Disinfectants business reflects ongoing portfolio simplification, which carries near-term execution and revenue-continuity risk.
3. Well-Resourced Competitors: Several competitors (notably large diversified life-science and animal-health companies) have greater financial resources than Neogen and can out-invest it in R&D or price aggressively in specific product lines.
4. No Dominant Single-Competitor Dynamic: Because Neogen's broad-portfolio strategy is unique, it also means it competes against different specialists in nearly every product category, limiting its ability to build an unassailable position in any one narrow niche.

---

6. Financial Overview

---

7. Summary Conclusion

Neogen Corporation occupies a differentiated position as one of the only companies with a broad, validated product line spanning both food safety and animal safety diagnostics — a breadth its own 10-K says no single competitor matches. Its moat rests on regulatory-embedded test methods that are costly for customers to re-validate elsewhere, and on the scale gained from the transformative 2022 combination with 3M's Food Safety Division. The key near-term risk is that the company has not yet turned that scale into margin or revenue growth — fiscal 2025 revenue and gross margin both declined — making successful integration execution, not competitive threat, the most important variable for Neogen's next few years.